249 related articles for article (PubMed ID: 24614598)
1. Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Sahin G; Thompson LH; Lavisse S; Ozgur M; Rbah-Vidal L; Dollé F; Hantraye P; Kirik D
PLoS One; 2014; 9(3):e90759. PubMed ID: 24614598
[TBL] [Abstract][Full Text] [Related]
2. Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
Nahimi A; Høltzermann M; Landau AM; Simonsen M; Jakobsen S; Alstrup AK; Vang K; Møller A; Wegener G; Gjedde A; Doudet DJ
J Neurochem; 2012 Mar; 120(5):806-17. PubMed ID: 22117574
[TBL] [Abstract][Full Text] [Related]
3. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
4. Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia.
Sellnow RC; Newman JH; Chambers N; West AR; Steece-Collier K; Sandoval IM; Benskey MJ; Bishop C; Manfredsson FP
Acta Neuropathol Commun; 2019 Jan; 7(1):8. PubMed ID: 30646956
[TBL] [Abstract][Full Text] [Related]
5. Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia.
Carta M; Bezard E
Neuroscience; 2011 Dec; 198():245-51. PubMed ID: 21840375
[TBL] [Abstract][Full Text] [Related]
6. Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Tseng KY; Kuo TT; Wang V; Huang EY; Ma KH; Olson L; Hoffer BJ; Chen YH
J Parkinsons Dis; 2022; 12(5):1545-1565. PubMed ID: 35599497
[TBL] [Abstract][Full Text] [Related]
7. Ondansetron, a highly selective 5-HT
Kwan C; Frouni I; Bédard D; Hamadjida A; Huot P
Eur J Pharmacol; 2020 Mar; 871():172914. PubMed ID: 31926127
[TBL] [Abstract][Full Text] [Related]
8. TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
Ikeda K; Yoshikawa S; Kurokawa T; Yuzawa N; Nakao K; Mochizuki H
Eur J Pharmacol; 2009 Oct; 620(1-3):42-8. PubMed ID: 19686730
[TBL] [Abstract][Full Text] [Related]
9. Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson's Disease.
Altwal F; Padovan-Neto FE; Ritger A; Steiner H; West AR
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641332
[TBL] [Abstract][Full Text] [Related]
10. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
[TBL] [Abstract][Full Text] [Related]
11. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Zhang H; Ma L; Wang F; Chen J; Zhen X
Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
[TBL] [Abstract][Full Text] [Related]
12. Imaging DA release in a rat model of L-DOPA-induced dyskinesias: a longitudinal in vivo PET investigation of the antidyskinetic effect of MDMA.
Lettfuss NY; Fischer K; Sossi V; Pichler BJ; von Ameln-Mayerhofer A
Neuroimage; 2012 Oct; 63(1):423-33. PubMed ID: 22766162
[TBL] [Abstract][Full Text] [Related]
13. Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.
Doo AR; Kim SN; Hahm DH; Yoo HH; Park JY; Lee H; Jeon S; Kim J; Park SU; Park HJ
BMC Complement Altern Med; 2014 Mar; 14():107. PubMed ID: 24650244
[TBL] [Abstract][Full Text] [Related]
14. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
15. The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.
Gil S; Park C; Lee J; Koh H
Cell Mol Neurobiol; 2010 Aug; 30(6):817-25. PubMed ID: 20232137
[TBL] [Abstract][Full Text] [Related]
16. The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease.
Altwal F; Moon C; West AR; Steiner H
Cells; 2020 Oct; 9(10):. PubMed ID: 33050305
[TBL] [Abstract][Full Text] [Related]
17. Globus pallidus, but not entopeduncular nucleus, 6-OHDA-induced lesion attenuates L-Dopa-induced dyskinesia in the rat model of Parkinson's disease.
Marin C; Bonastre M; Fuentes M; Mullol J
Pharmacol Biochem Behav; 2020 Oct; 197():173013. PubMed ID: 32758524
[TBL] [Abstract][Full Text] [Related]
18. Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat.
Bhide N; Lindenbach D; Barnum CJ; George JA; Surrena MA; Bishop C
J Neurochem; 2015 Jul; 134(2):222-32. PubMed ID: 25866285
[TBL] [Abstract][Full Text] [Related]
19. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
Carta M; Lindgren HS; Lundblad M; Stancampiano R; Fadda F; Cenci MA
J Neurochem; 2006 Mar; 96(6):1718-27. PubMed ID: 16539687
[TBL] [Abstract][Full Text] [Related]
20. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]